PMID- 35975373
OWN - NLM
STAT- MEDLINE
DCOM- 20220818
LR  - 20220818
IS  - 1119-3077 (Print)
VI  - 25
IP  - 8
DP  - 2022 Aug
TI  - Intravenous immunoglobulin in hemolytic disease of the newborn: A moving target 
      in time.
PG  - 1262-1268
LID - 10.4103/njcp.njcp_1_22 [doi]
AB  - BACKGROUND: Alloimmune hemolytic disease of the newborn (AIHDN) results in 
      hemolysis, anemia, hyperbilirubinemia with the potential for brain damage. 
      Intravenous immunoglobulin (IVIG) has been investigated as an alternative 
      low-risk procedure for the treatment of AIHDN in addition to traditional 
      treatment methods such as phototherapy and exchange transfusion (ET). AIM: To 
      evaluate the effectiveness of IVIG therapy in decreasing ET needs based on risk 
      factors and clinical outcomes. MATERIALS AND METHODS: Charts of neonates born >30 
      weeks of gestation who underwent phototherapy and were administered IVIG therapy 
      due to AIHDN between January 2013 and July 2018 were retrospectively reviewed. 
      RESULTS: Sixty-three neonates were included in our study. Forty-three of them 
      (68.3) % were full-term infants. ABO incompatibility (n = 33, 52.4%) was the 
      major cause of AIHDN (n = 63). Additional risk factors for jaundice were found to 
      coexist in 95.2% (n = 60) of the infants. Fifteen infants (23.8%) required ET, 
      mostly due to Rh incompatibility (n = 11, 73.3%). Mortality was observed in 3.2% 
      (n = 2) of the patients, 1.6% (n = 1) of whom were related to ET. Serum albumin 
      value was found to be negatively correlated with the requirement for ET (r = 
      0.713, P < 0.001), whereas serum bilirubin albumin ratio was positively 
      correlated (r = 0.489, _P < 0.001). Nine (14.3%) infants needed a simple 
      transfusion during the hospitalization period, whereas five (7.9%) infants had 
      readmission for simple transfusion after discharge. Apnea was the only 
      complication seen in one (1.6%) patient. CONCLUSION: IVIG treatment should be 
      considered due to its relative benefits when compared to exchange transfusion. In 
      addition to its safety, it is a less complicated treatment modality with low side 
      effect rates. It may be justified for elective use in neonates suffering from 
      AIHDN, who will require ET with a risk of mortality by decreasing the peak of 
      total serum bilirubin levels.
FAU - Vardar, G
AU  - Vardar G
AD  - Department of Neonatology, University of Health Sciences, Zeynep Kamil Maternity 
      and Children's Disease Health Training and Research Center-Istanbul, Turkey.
FAU - Okan, M A
AU  - Okan MA
AD  - Department of Neonatology, University of Health Sciences, Zeynep Kamil Maternity 
      and Children's Disease Health Training and Research Center-Istanbul, Turkey.
FAU - Karadag, N
AU  - Karadag N
AD  - Department of Neonatology, University of Health Sciences, Zeynep Kamil Maternity 
      and Children's Disease Health Training and Research Center-Istanbul, Turkey.
FAU - Topcuoglu, S
AU  - Topcuoglu S
AD  - Department of Neonatology, University of Health Sciences, Zeynep Kamil Maternity 
      and Children's Disease Health Training and Research Center-Istanbul, Turkey.
FAU - Ozalkaya, E
AU  - Ozalkaya E
AD  - Department of Neonatology, University of Health Sciences, Zeynep Kamil Maternity 
      and Children's Disease Health Training and Research Center-Istanbul, Turkey.
FAU - Karatepe, H O
AU  - Karatepe HO
AD  - Department of Neonatology, University of Health Sciences, Zeynep Kamil Maternity 
      and Children's Disease Health Training and Research Center-Istanbul, Turkey.
FAU - Karatekin, G
AU  - Karatekin G
AD  - Department of Neonatology, University of Health Sciences, Zeynep Kamil Maternity 
      and Children's Disease Health Training and Research Center-Istanbul, Turkey.
LA  - eng
PT  - Journal Article
PL  - India
TA  - Niger J Clin Pract
JT  - Nigerian journal of clinical practice
JID - 101150032
RN  - 0 (Immunoglobulins, Intravenous)
RN  - RFM9X3LJ49 (Bilirubin)
SB  - IM
MH  - Bilirubin
MH  - *Erythroblastosis, Fetal/drug therapy
MH  - Female
MH  - Hemolysis
MH  - Humans
MH  - *Immunoglobulins, Intravenous/therapeutic use
MH  - Infant
MH  - Infant, Newborn
MH  - Retrospective Studies
OTO - NOTNLM
OT  - Alloimmune hemolytic disease of the newborn
OT  - exchange transfusion
OT  - intravenous immunoglobulin
OT  - phototherapy
COIS- None
EDAT- 2022/08/18 06:00
MHDA- 2022/08/19 06:00
CRDT- 2022/08/17 02:43
PHST- 2022/08/17 02:43 [entrez]
PHST- 2022/08/18 06:00 [pubmed]
PHST- 2022/08/19 06:00 [medline]
AID - NigerJClinPract_2022_25_8_1262_353783 [pii]
AID - 10.4103/njcp.njcp_1_22 [doi]
PST - ppublish
SO  - Niger J Clin Pract. 2022 Aug;25(8):1262-1268. doi: 10.4103/njcp.njcp_1_22.